Finishing lamb performance responses to bovine and porcine somatotropins administered by Alzet pumps.

Daily injection of ovine and bovine somatotropin (oST and bST, respectively) has been shown to improve performance and carcass quality of finishing lambs. To evaluate responses to continuously released bST and porcine ST (pST), which have 99 and 91% sequence homology with oST, respectively, finishing lambs were implanted with 2-wk Alzet pumps containing bST or pST, which was released at rates of 2 or 4 mg/d. Six-week growth rate and feed efficiency responses to bST were greater than those to pST (P less than .05). Overall feed efficiency was improved 15% and growth rate was increased 16% in lambs treated with 4 mg/d of bST compared with control lambs and neither trait was affected in pST-treated lambs. Performance responses were reflected by changes in circulating glucose, blood urea nitrogen, and insulin-like growth factor I (IGF-I) concentrations. Scatchard analysis of sera with relative binding of greater than 30% revealed that average binding capacities and affinities of pST-treated lambs were 7.0 mg/liter and 6.0 x 10(9) liters/mol, respectively, and of bST-treated lambs were .8 mg/liter and 1.3 x 10(9) liters/mol, respectively. In addition, lambs with high-capacity pST antibodies had lower 6-wk IGF-I concentrations than those of controls, suggesting that these antibodies may have been attenuating responsiveness to pST. It is concluded that continuously released bST, but not pST, improves performance of finishing lambs.     

The influence of level of feeding on growth and serum insulin-like growth factor I and insulin-like growth factor-binding proteins in growing beef cattle supplemented with somatotropin

The objective of this study was to determine the effects of level of feeding on growth, feed efficiency (gain:feed; G:F), body composition (BC), and serum concentrations of somatotropin (ST), IGF-I, and IGF-binding proteins (BP) in growing beef cattle supplemented with bovine (b) ST. In each of two consecutive years, 40 growing beef cattle were blocked by weight (average BW: yr 1 = 316 kg, yr 2 = 305 kg) and used in a 2 x 2 factorial arrangement with main effects of bST (0 or 33 microg x kg BW(-1) x d(-1)) and level of feed intake (ad libitum [AL] or 0.75 AL). Relative to uninjected cattle, treatment with bST increased ADG 9.6% (1.14 vs 1.25 kg/d; P < 0.05) and increased G:F 8.1% (12.3 vs 13.3 gain [g]:feed [kg]; P < 0.05), whereas ADG in AL animals was 39% greater than that in 0.75 AL animals (1.39 vs 1.00 kg/d; P < 0.05). There was a tendency (P = 0.10) for a bST x level of feeding interaction, such that the increase in ADG with bST was greater in AL cattle than in 0.75 AL cattle (10.6 vs 7.8%; P = 0.10). Serum concentrations of ST were greater in 0.75 AL cattle than in AL cattle (13.0 vs 8.6 ng/mL; P < 0.05) and in bST-treated cattle than in uninjected cattle (16.3 vs 5.2 ng/mL; P < 0.05). Due to a bST x level of feeding interaction (P < 0.01), the magnitude of the increase in serum ST to exogenous bST was greater (P < 0.01) in 0.75 AL cattle than in AL cattle. Relative to uninjected cattle, treatment with bST increased (P < 0.05) serum concentrations of IGF-I and IGFBP-3 and reduced (P < 0.05) concentrations of IGFBP-2. Similarly, AL cattle had greater (P < 0.05) serum concentrations of IGF-I and IGFBP-3 and reduced (P < 0.05) IGFBP-2 compared with 0.75 AL cattle. In summary, treatment with bST increased growth rate and G:F and stimulated serum IGF-I and IGFBP-3 while reducing IGFBP-2. Feeding at 0.75 ad libitum intake reduced the magnitude of response for each of these variables. Thus, limit-feeding may reduce the effect of exogenous bST on growth rate by blunting bST-induced increases in IGF-I and IGFBP-3 and bST-induced decreases in IGFBP-2.     

The ontogeny of the somatotropic axis in Hereford calves from birth to one year of age and its response to administration of exogenous bovine somatotropin

Administration of exogenous bovine ST (bST) increases growth rate, feed efficiency, and carcass quality in beef cattle. The magnitude of response to bST in beef cattle is variable and related to the age of the animal. Our objective was to determine the response of the somatotropic axis, in particular IGF-I, IGFBP-2, and IGFBP-3, to bST treatment from birth to 1 yr of age. Blood samples were collected before and after a single injection of bST (500 mg) every 50 d from birth to 1 yr of age in male and female Hereford calves. Body weights and serum concentrations of ST, IGF-I, IGFBP-2, and IGFBP-3 were determined. At birth, serum concentrations of ST, IGF-I, and IGFBP-3 increased (P < 0.05) following bST treatment. From 50 to 350 d of age, average concentrations of ST and IGF-I were greater (P < 0.05) in males, whereas IGFBP-2 concentrations were greater (P < 0.05) in females. No gender differences in IGFBP-3 concentrations were observed. Following bST treatment, IGF-I increased (P < 0.05) from 50 to 350 d of age, IGFBP-2 decreased (P < 0.05) from 50 to 200 d of age, and IGFBP-3 increased (P < 0.05) at 250 d of age. At 250 d of age, baseline concentrations of IGFBP-2 decreased (P < 0.05). Due to the positive response of IGFBP-3 and decreased baseline IGFBP-2 at 250 d of age, we conclude that this is an age at which the somatotropic axis is most responsive to exogenous bST, and it therefore may be an appropriate age to begin bST treatment in beef calves to realize the positive influence of bST on BW gain, feed efficiency, and carcass composition.     

Effect of pituitary somatotropin injections on plasma insulin-like growth factor I and somatotropin profiles in growing heifers

Effects of daily injections of pituitary-derived bovine somatotropin (bST) for 6 wk were evaluated in 10 growing heifers and compared to 9 placebo-treated control animals. Bovine somatotropin was injected at 50 micrograms/kg BW each day. Body weight and growth, plasma concentrations of insulin-like growth factor I (IGF-I) and somatotropin (ST) were assessed. To measure plasma concentrations of IGF-I, we validated a RIA in which bovine plasma samples were extracted with acid-ethanol, a method that resulted in greater than 90% recovery of IGF-I. Average daily gain was similar during the first 4 wk of the experiment in both control and bST-treated groups; however, at the end of the experimental period (wk 4 and 6) ADG was greater (P less than .05) in bST-treated heifers (1.24 +/- .21 kg/d vs .75 +/- .25 kg/d). Plasma IGF-I from wk 2 to wk 6 were increased in bST-treated animals (452 +/- 97 ng/ml at wk 2; 683 +/- 106 ng/ml at wk 6) compared with controls (293 +/- 62 ng/ml at wk 2 (P less than .01) and 293 +/- 115 ng/ml at wk 6 (P less than .001). Moreover, ADG over the 6-wk experimental period was correlated with mean IGF-I concentrations determined over the same period (r = .55; P less than .01). As expected, mean plasma ST concentrations were increased in bST-injected animals from wk 1 to 6. Gel chromatographic profiles of bovine plasma exhibit a 150,000 molecular weight ST-dependent binding protein-IGF-I complex and a 30,000 molecular weight non-ST-dependent complex. This study validates a method for measuring IGF-I in cattle, and shows a positive relationship among IGF-I and ADG after ST treatment. No correlation, however, was found between plasma ST and growth performance.     

Changes in hormones, metabolites, and milk after treatment with sometribove (recombinant methionyl bST) in Deutsches Fleckvieh and German black and white cows

Twelve second-lactation Deutsches Fleckvieh cows, (FV, a dual-purpose breed) and 12 German Black and White (BW, a dairy breed) were used to evaluate similarities and differences in the response to a prolonged-release formulation of sometribove (N-methionyl bovine somatotropin, bST). Cows were milked twice daily and fed a basic diet (70% corn silage, 30% alfalfa hay) ad libitum plus 1 kg of concentrate. Additionally, concentrates and supplements were offered at the rate of 1 kg for each 22 kg of milk produced above 12 kg/d. Six cows of each breed were treated s.c. with 500 mg of sometribove at 14-d intervals from wk 9 to 29 postpartum (pp). Blood was collected by jugular vein puncture once weekly from wk 7 to 33 pp and daily for 14 d after the first and last (11th) injection of bST. Somatotropin (ST), insulin-like growth factor I (IGF-I), insulin, thyroid hormones, nonesterified fatty acids (NEFA), liver enzymes, and blood metabolites were evaluated. During bST treatment, plasma ST increased significantly on d 7 in both breeds and then decreased on d 14 after injection. Plasma IGF-I was positively correlated with ST. Plasma NEFA were high on d 7 and decreased on d 14. In response to bST, the average milk yield increased for FV and BW cows by 5.1 kg/d (29.7%) and 5.0 kg/d (28%), respectively, and 4% fat-corrected milk (FCM) increased by 5.0 kg/d (28%) and 5.3 kg/d (19.9%), respectively. Milk content of fat, protein, lactose, number of somatic cells, and body weight were similar across treatments.(ABSTRACT TRUNCATED AT 250 WORDS)     

Endocrine factors and ovarian follicles are influenced by body condition and somatotropin in postpartum beef cows

Multiparous beef (1/4 to 3/8 Bos indicus; n = 99) cows were managed to achieve low (BCS = 4.3 +/- 0.1; n = 50) or moderate (BCS = 6.1 +/- 0.1; n = 49) body condition (BC) to determine the influence of bovine (b) ST on the number of follicles, diameter of largest follicle, and serum concentrations of IGF-I, triiodothy-ronine (T3), thyroxine (T4), and prolactin. Beginning 32 d postpartum, cows within each BC were assigned randomly to treatment with or without bST. Non-bST-treated cows received no treatment, and treated cows were administered bST (Posilac, 500 mg, s.c.) on d 32, 46, and 60 postpartum. On d 60, all cows received a controlled internal drug-releasing (CIDR) device for 7 d and PGF(2alpha) at CIDR removal (CIDR-PGF(2alpha)). Blood samples (7 mL) were collected at each bST treatment and d 39 and 67 postpartum. Ultrasound was performed 1 d after CIDR-PGF(2alpha) to determine the number of small (2 to 9 mm) and large (>/=10 mm) follicles and the diameter of largest follicle. Cows treated with bST in low BC had increased (P < 0.05) IGF-I vs. low-BC non-bST-treated cows on d 39, 46, 60, and 67 postpartum. Prolactin and T3 were greater (P < 0.05) in moderate-BC than in low-BC cows on all sample dates. Thyroxine was greater (P < 0.001) in moderate-BC cows on d 46, 60, and 67 compared with low-BC cows. On d 67, bST-treated cows had greater (P < 0.05) T4 compared with non-bST-treated cows. Diameter of the largest follicle 1 d after CIDR-PGF(2alpha) was greater (P < 0.01) in anestrous cows treated with bST than for non-bST-treated anestrous cows. Diameter of the largest follicle was correlated with concentrations of IGF-I (r >/= 0.18; P /= 0.17; P /= 0.20; P 相似文献   

The ontogeny of the somatotropic axis in male and female Hereford calves from birth to one year of age

Insulin-like growth factor-binding proteins-2 and -3 may play a role in age-dependent growth response to bovine ST (bST) treatment in cattle; however, samples have been collected at infrequent intervals and at limited time points. Therefore, the objective of this experiment was to examine the ontogeny of components of the somatotropic axis in Hereford calves from birth to 1 yr of age at weekly intervals to determine whether there is a certain age or time frame when the somatotropic axis may change and/or potentially become more responsive to exogenous bST administration. Blood samples and body weight measurements were collected from eight male and eight female Hereford calves once per week from birth to 1 yr of age. Serum concentrations of ST, IGF-I, IGFBP-2, and IGFBP-3 were determined. Males began to grow faster than females at approximately 16 wk of age (P < 0.05). Average concentrations of ST, IGF-I, and IGFBP-3 were greater in males than females (P < 0.01). Average concentrations of IGFBP-2 were greater in females than in males (P = 0.05). Concentrations of ST decrease with age (P < 0.01); however, the decrease occurred earlier in female calves. Concentrations of IGF-I and IGFBP-3 increased in males and females (P < 0.01), and concentrations of IGF-I began to plateau at approximately the same time as growth rate differences were observed (16 wk of age). Following an initial increase (birth to approximately 16 wk of age), concentrations of IGFBP-3 remained constant until approximately 43 wk of age. Concentrations of IGFBP-2 increased to approximately 10 wk of age (P < 0.05), followed by a decrease, and then, similar to IGFBP-3, remained constant until 43 wk of age. Correlations between average daily gain, ST, IGF-I, IGFBP-2, and IGFBP-3 were determined. Average daily gain was negatively (P < 0.01) correlated with ST and positively (P < 0.1) correlated with IGF-I. In females, ST was negatively (P < 0.01) correlated with IGF-I. Concentrations of ST were positively correlated (P < 0.01) with IGFBP-2 and IGFBP-3. Concentrations of IGFBP-2 were negatively correlated (P < 0.01) with IGF-I and positively correlated (P < 0.01) with IGFBP-3. In conclusion, serum concentrations of ST, IGF-I, IGFBP-2, and IGFBP-3 differed between male and fe-male calves. In addition, changes in components of the somatotropic axis occurred around the same time as males began to grow faster than females.     

Insulin-like growth factor I receptor analysis of satellite cell-derived myotube membranes established from two lines of Targhee rams selected for growth rate

Ovine-derived fibroblasts were used to validate an insulin-like growth factor I (IGF-I) membrane-receptor binding assay system. Competitive binding using fibroblasts revealed that half-maximal inhibition of 125I-IGF-I binding by IGF-I was 2.3 nM. SDS-polyacrylamide gel electrophoresis analysis of specific protein-associated 125I-IGF-I was consistent with the migration of 125I-IGF-I-labeled Type I IGF receptor alpha-subunits at Mr 133,000 daltons. Further, the efficiency of two cell solubilization methods was examined and time-dependent binding equilibrium was determined for the membrane assay system. Satellite cell-derived myotubes were subsequently isolated from primary satellite cell cultures established from the semimembranosus muscles of high and low efficiency-of-gain (EOG) Targhee rams, and IGF-I receptor dynamics were measured. A membrane competitive binding study revealed that half-maximal inhibition of 125I-IGF-I binding was achieved by 1-ng IGF-I for low, and 10-ng IGF-I for high, EOG myotube membrane preparations. Kd values were similar between the high EOG (4.78 nM) and low EOG (2.95 nM) groups; however, receptor concentrations (Bmax) appeared to differ between groups. High EOG membrane receptor Bmax was 3.88 pmole/micrograms protein (19.87 pmole/micrograms DNA), whereas low EOG membrane receptor Bmax was 1.22 pmole/micrograms protein (9.28 pmole/micrograms DNA). These preliminary findings support the hypothesis that genetic selection for EOG results in altered satellite cell responsiveness to IGF-I.     

Temporal pattern of insulin-like growth factor-I response to exogenous bovine somatotropin in lactating cows

The effect of exogenous bovine somatotropin (bST) treatment on the temporal pattern of insulin-like growth factor-I (IGF-I) in serum of four multiparous Holstein cows was examined. Cows (190 +/- 24 days postpartum) were treated with daily subcutaneous injections of recombinant bST (40 mg) or excipient for 12-day periods in a crossover experimental design. During excipient treatment, concentrations of IGF-I in serum were relatively constant throughout the day and averaged 70 ng/ml. Following the first bST injection, serum IGF-I began increasing after a lag of 5 to 7 hr and progressively increased over the first 2 days of treatment. Serum IGF-I levels were approximately 2-fold greater than control values at the end of day 1 of bST treatment, with a 3-fold elevation observed at the end of day 2. Concentrations of IGF-I in serum plateaued by day 3 of bST treatment. Serum concentrations of IGF-I did not follow the oscillating pattern of bST in serum resulting from daily bST injections. Milk yield (3.5% fat-corrected) plateaued after 6 days of bST treatment and was increased 61% (+15.3 kg). Both IGF-I and milk yield remained essentially constant across days for the remainder of treatment. Following cessation of treatment, serum IGF-I and milk yield gradually declined, returning to control values after approximately 4 days. The temporal pattern of circulating concentrations of IGF-I is consistent with a role for IGF-I in mediating a portion of the effects of exogenous bST in lactating cows.     

Interaction of insulin-like growth factor I with turkey satellite cells and satellite cell-derived myotubes

Satellite cells, isolated from the superficial pectoralis muscle of growing Nicholas tom turkeys, were cloned to obtain a pure population of myogenic cells. These cells proliferated rapidly and differentiated (fused) into myotubes typically containing 92-98% fused nuclei. Competitive binding assays were performed on near-confluent satellite cell or myotube cultures in 35 mm diameter wells by adding [125I]IGF-I along with increasing concentrations of unlabeled IGF-I, IGF-II, or insulin. Following incubation, the cultures were washed to remove the unbound hormones, solubilized with 0.5 N NaOH, and the radioactivity specifically bound was determined. Total and fused nuclei number as well as total protein were determined in parallel cultures. Our results indicate that turkey satellite cell and myotube cultures possess specific binding sites for IGF-I. Displacement of [125I]IGF-I was in the order of IGF-I greater than IGF-II greater than or equal to insulin. Although the [125I]IGF-I association constants were similar for turkey satellite cells and myotubes, a 2.8-fold decrease in the number of receptors per nuclei was observed as satellite cells differentiated into myotubes. The 50% inhibition constants for IGF-I, IGF-II, and insulin were 3.7 X 10(-9) M, 7.5 X 10(-8) M, and 8.7 X 10(-8) M for satellite cells and 3.1 X 10(-9) M, 7.5 X 10(-8) M, and 9.6 X 10(-8) M for myotubes, respectively. Receptor cross-linking analysis using disuccinimidyl suberate was performed on near-confluent satellite cell cultures incubated with [125I]IGF-I in the presence or absence of 1 X 10(-7) M IGF-I, IGF-II, or insulin. Receptor subunit species of Mr 130 kDa and 98 kDa were observed under reducing conditions (100 mM dithiothreitol) and at a Mr greater than 300 kDa (native receptor tetramer) under non-reduced conditions. Autoradiographic bands were displaced with IGF-I but not with equimolar levels of IGF-II or insulin. The results suggest that turkey satellite cells possess a type I IGF receptor.     

Hematological profiles in dairy cows treated with recombinant bovine somatotropin.

Recombinant bovine somatotropin (bST) was administered at 0, 10.3, or 20.6 mg per cow per day to 32 Holsteins for 38 wk. Fifteen currently treated cows had been treated in the previous lactation. Eighteen hematological variables and blood concentration of insulin-like growth factor I (IGF-I) were measured at five sample periods. The objectives of the study were to test the effects of bST treatments on hematological profiles and to relate blood IGF-I concentration to these variables. Results indicated little influence (P greater than .10) of previous bST treatments on hematological profiles measured in the current lactation. Current bST treatments, however, altered hematocrits (P = .10), mean corpuscular volume (P = .03), mean corpuscular hemoglobin (P = .009), and fraction of blood lymphocytes (P = .09). A week x bST treatment interaction also contributed to variation in hematocrit (P = .09), mean corpuscular hemoglobin (P = .05), fraction of neutrophils (P = .02), and fraction of lymphocytes (P = .04). Blood IGF-I concentration influenced fractions and counts of neutrophils (P = .06, .09), lymphocytes (P = .04, .02), and monocytes (P = .08, .05). Further in vivo and in vitro studies are warranted because this preliminary evidence suggests that bST and(or) IGF-I contribute to regulation of hematopoiesis in mature dairy cows.     

Somatotropin and insulin-like growth factor-I concentrations in plasma and milk after daily or sustained-release exogenous somatotropin administrations

Effects of daily injectable or sustained-release bovine somatotropin (bST) administrations on plasma and milk bST and insulin-like growth factor-I (IGF-I) concentrations were monitored in 74 lactating cows through early, mid- and late lactation. Treatments beginning at wk 4 of lactation were excipient (CO, 24 cows) at 2 wk intervals, daily injections of 10.3 mg bST (DI, 25 cows) and 350 mg sustained-release bST at 2 wk intervals (SR, 25 cows). The duration of treatments was 40 wk. Data were first analyzed for the overall mean concentrations covering the 40 wk treatment period. Overall mean plasma bST, milk bST and plasma IGF-I concentrations were significantly increased by both bST treatments (p<0.05). On the other hand, milk IGF-I concentrations were significantly increased (p<0.05) only in the DI group. Next, data were analyzed according to stage of lactation. The bST treatments resulted in significant increases (p<0.05) in plasma and milk bST concentrations for all early, mid- and late lactation periods. Even though plasma IGF-I concentrations were higher (p<0.05) in all lactation periods for bST treatment groups, higher milk IGF-I concentrations (p<0.05) occurred only in mid- and late lactation periods for the DI group. The patterns of bST and IGF-I concentrations in milk follows those of the plasma after bST treatments.     

Growth rate and changes of the somatotropic axis in beef cattle administered exogenous bovine somatotropin beginning at two hundred, two hundred fifty, and three hundred days of age

To determine the effects of bovine somatotropin (bST) treatment beginning at 3 ages on the growth rate and components of the somatotropic axis, 40 beef cattle (200 +/- 21 d of age) were randomly assigned to 1 of 4 treatments (10 animals/treatment). Three of the treatment groups received bST (33 mug/kg of BW) daily beginning at 200, 250, or 300 d of age until all animals reached 400 d of age; the fourth group served as controls (0 bST). Animals were housed in pens (5 animals per pen; 2 pens per treatment) and fed a diet formulated for an ADG of 1.2 kg/d. Feed intake (per pen) was measured daily, and BW was determined weekly. Blood samples (10 mL) and ultrasound measurements were collected at 200, 250, 300, 350, and 400 d of age. Serum concentrations of ST and IGF-I were determined by RIA and IGFBP-2 and -3 by ligand blot procedures. Overall, cattle gained 284.0 +/- 14.7 kg of BW with a treatment x week interaction (P < 0.01), such that during the treatment period ADG was 11.6, 8.7, and 15.8% greater (P < 0.05) in cattle treated with bST beginning at 200, 250, and 300 d, respectively, relative to controls during the same time frame. Average DMI was 13.6% less (P < 0.05) in bST-treated cattle than in controls. Increases in ADG coupled with a reduction in DMI resulted in 11.7, 14.0, and 26.4% increases (P < 0.01) in the efficiency of gain (G:F) in bST-treated cattle beginning at 200, 250, and 300 d of age, respectively, compared with contemporary controls. Backfat thickness increased (P < 0.05) over time, but the magnitude of the increase was less in the bST-treated cattle (treatment x week interaction; P < 0.05). Area of the LM increased (P < 0.05) over time but was similar across treatment groups. Serum concentrations of ST, IGF-I, and IGFBP-3 increased (P < 0.05), whereas IGFBP-2 decreased (P < 0.05) over time. The changes in the components of somatotropic axis were more pronounced in bST-treated cattle compared with controls, with the greatest magnitude of response in animals that began bST treatment at 300 d of age. In conclusion, the exogenous bST-induced growth response was greater in animals that began to receive bST administration at 300 d of age and received it for a shorter period (100 d) compared with animals that received bST beginning at 200 or 250 d of age.     

Comparison of insulin-like growth factor I serum binding proteins in sheep and cattle: species differences in size and endogenous binding capacities

Binding proteins (BP) for insulin-like growth factor I (IGF-I) were characterized in sheep and beef cattle serum for molecular weight (Mr) and binding characteristics. Serum was incubated with [125I] IGF-I at 37 degrees C before chromatography over a 1.6-cm X 94.0-cm column of Sephacryl S-300 (pH 7.4, 4 degrees C). Beef serum exhibited a 145 k Mr (mol. wt X 1,000) and a 35 to 39 k Mr BP. Sheep serum possessed a 170 to 190 k and a 35 to 38 k Mr protein. Binding of [125I] IGF-I was inhibited in the presence of excess unlabeled ovine somatomedin, demonstrating specific binding for each BP of both species. The high Mr component was pituitary-dependent in sheep, as evidenced by binding patterns from serum of hypophysectomized sheep. Direct binding studies of the Sephacryl-separated BP demonstrated that the native BP of high molecular weight of both species bound only minor amounts of [125I] IGF-I in a manner unrelated to BP concentration. The BP of low molecular weight of beef cows displayed a bell-shaped dose-response binding curve with maximum binding at 250 micrograms/ml BP, whereas binding to sheep BP of low molecular weight was independent of BP concentration. After chromatography on Sephadex G50 at pH 2.8, both BP from both species exhibited concentration-dependent binding that plateaued at 250 to 500 micrograms/ml of BP of low molecular weight but was curvilinear for the BP of high molecular weight.(ABSTRACT TRUNCATED AT 250 WORDS)     

Use of bovine somatotropin for increased skeletal and lean tissue growth of Holstein steers

One hundred-sixty Holstein growing-finishing steers (initial BW of 185 kg) were blocked by BW to determine the effectiveness of long-term bovine somatotropin (bST) administration on lean, skeletal, and carcass measurements. Steers were randomly allocated to 4 treatments (10 steers/treatment) within a block (n = 4 blocks). Treatments were control, no bST (C-C); bST from d 0 to 182 (bST-C); bST from d 183 to slaughter (C-bST); and bST from d 0 to slaughter (bST-bST). Steers received a s.c. injection of placebo or bST at 14-d intervals. Doses were 320 mg of bST/injection from d 0 to 112 and 640 mg of bST/injection from d 113 to slaughter. The last treatment was administered 31 d before slaughter. Steers received a 14% CP (DM basis) diet from d 0 to 182 and 11.5% CP from d 183 to slaughter that consisted of dry, whole-shelled corn and a pelleted protein-mineral supplement. Steers were slaughtered when BW per block averaged 615 kg (d 325, 353, 367, and 381 for the 4 blocks, respectively). Thirty steers were removed from the study because of poor performance with respect to their pen mates, illness, lameness, death, incomplete castration, and incorrect treatment. Serum IGF-I concentrations increased 151% (P < 0.01) from d 7 through 35 in bST-treated steers compared with control steers. During the first 182 d, bST-C and bST-bST steers were heavier (P < 0.01) and had greater (P < 0.01) ADG, G:F, hip height, and hip height gain compared with C-C and C-bST steers. From d 183 to slaughter, C-bST steers had reduced (P < 0.05) daily DMI and greater G:F than bST-C steers. At final slaughter, C-bST and bST-bST steers had greater (P < 0.05) hip height than C-C steers. Noncarcass weight was increased and dressing percent reduced (P < 0.05) in C-bST and bST-bST steers compared with C-C steers. Quality grade was least (P < 0.05) in bST-bST carcasses compared with C-C, whereas bST-C and C-bST carcasses were intermediate. At final slaughter, steers receiving bST had greater (P < 0.05) carcass protein and water composition and lower (P < 0.05) carcass lipid and lipid accretion than C-C steers. Bovine somatotropin was effective in reducing carcass fat and increasing edible lean. Administering bST to young, lightweight steers increased skeletal growth and noncarcass weight without an increase in total carcass weight, but decreased carcass quality.     

Serum hormone profiles, pregnancy rates, and offspring performance of Rambouillet ewes treated with recombinant bovine somatotropin before breeding

An experiment was conducted to examine effects of bovine ST (bST) on serum hormone concentrations, pregnancy rates, and offspring performance. Before initiation of a fall breeding period, 75 Rambouillet ewes (68.8 ± 1.5 kg) received an intravaginal insert containing 0.3 g of progesterone (P4) to synchronize onset of estrus. After 12 d, inserts were removed (d 0), and ewes (stratified by BW and age) received either 0 (control, n = 37) or 250 (n = 38) mg of recombinant bST (Posilac, Monsanto, St. Louis, MO, subcutaneously). Ewes were joined with fertile rams 24 h after insert removal. Blood samples were collected from 12 ewes in each treatment group daily from d 0 to 20 after insert removal. Serum IGF-I concentrations were 315 and 437 (± 58) ng/mL in control and bST-treated ewes 2 d after receiving bST (P = 0.02) and remained increased (P < 0.03) in bST-treated ewes throughout the 13-d period (P < 0.05). Serum prolactin (P > 0.10) and estradiol (P = 0.65) were similar between treatments. Serum triiodothyronine (T3) and thyroxine (T4) concentrations were similar (P > 0.20) between treatments from d 0 through 8. Controls had greater (P < 0.04) serum T3 and T4 concentrations than treated ewes did until d 18. Serum P4 was similar (P > 0.10) in control and bST-treated ewes from d 0 through 3 but was increased (P < 0.05) from d 4 to 8 in control ewes. Serum P4 was again similar (P > 0.10) between treatments from d 9 to 20. Serum insulin concentrations were 0.44 and 1.74 (± 0.19) ng/mL in control and bST-treated ewes, respectively, 1 d after receiving bST (P < 0.001) and remained increased (P < 0.03) in bST-treated ewes through d 9 (P < 0.03). Serum glucose was increased (P = 0.003) from d 0 to 10 in bST-treated ewes compared with controls. Thirty-three of 37 (89%) control ewes were pregnant, whereas 27 of 38 (71%) bST-treated ewes were pregnant (P = 0.05). As a percentage of ewes lambing, 61% and 39% of control ewes produced single and twin lambs, respectively, compared with 41% and 59% of bST-treated ewes (P = 0.12). Lamb 60-d adjusted weaning weights were 23.0 and 21.2 (± 0.65) kg for offspring produced by control and bST-treated dams, respectively (P = 0.04). In conclusion, serum IGF-I, insulin, and glucose were greater whereas serum T3, T4, and P4 were less in bST-treated ewes than in controls. Pregnancy rates and offspring adjusted weaning weights were decreased by bST treatment immediately before breeding.     

Effect of bovine somatotropin and food deprivation on β-adrenergic and A1 adenosine receptor binding in adipose tissue of lactating cows

Lactating Holstein cows were used to assess the effect of bovine somatotropin (bST; n = 8) and fasting (FAST; n = 4) on ligand binding to β-adrenergic (BAR) and TYP e-1 adenosine (A₁R) receptors in adipose tissue. Cows received exogenous bST (sometribove; 40 mg/d) or no hormone (control) for 4 d in a single-reversal design with a 7-d interval between treatment periods. Subcutaneous adipose tissue biopsies were taken on day 4 of each treatment. Eight d after the bST regimen, 4 cows were fasted for 3 d and adipose biopsies were taken. Ligand binding was quantified with a postnuclear, total adipose tissue membrane preparation (100,000 × g pellet). Binding to BAR and A₁R was assessed with the antagonists [¹²⁵I]iodocyanopindolol (ICP) and [³H]8-cyclopentyl-1,3-dipropylxanthine (DCPCX), respectively. The binding affinity (K_d) of BAR for ICP was not affected by bST but was enhanced by FAST; maximal binding (B_max) was increased with bST treatment (P < 0.06) and reduced by FAST (61%, P < 0.01). K_d values for DCPCX binding to A₁R were not changed by bST or FAST. bST did not affect B_max for A₁R; however, FAST reduced the B_max by 38%. Data highlight the differential regulation of BAR and A₁R by bST and FAST.